Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia
Citation
Kekilli, M., Tanoğlu, A., Kızıl Çakar, M., Güney, G., Haznedaroğlu, İ. C. (2016). Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia. Uluslararasi Hematoloji Onkoloji Dergisi, 26(1), 67-68.Abstract
Dear Editor, Dasatinib is an orally administered, potent, secondline tyrosine kinase inhibitor which is used for treating imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia.
